Share Name Share Symbol Market Type Share ISIN Share Description
GlaxoSmithKline LSE:GSK London Ordinary Share GB0009252882 ORD 25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +24.50p +1.66% 1,504.00p 1,503.50p 1,504.00p 1,504.00p 1,482.50p 1,482.50p 6,794,256 16:29:55
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 27,889.0 1,939.0 18.8 80.0 73,852.32

GlaxoSmithKline Share Discussion Threads

Showing 14951 to 14974 of 14975 messages
Chat Pages: 599  598  597  596  595  594  593  592  591  590  589  588  Older
DateSubjectAuthorDiscuss
23/8/2017
00:18
'GlaxoSmithKline partners with Alibaba for China HPV vaccine market grab' HTTP://www.fiercepharma.com/vaccines/glaxosmithkline-partners-alibaba-for-china-hpv-vaccine-market-grab
philanderer
22/8/2017
23:49
Going up, not down, see you at 1715p next spring
ny boy
21/8/2017
12:13
Pendulum should swing on the other side
action
21/8/2017
08:36
Added back a few I sold at 1509, may have another few if we dip below 1460.
essentialinvestor
20/8/2017
09:48
#GSK faces row over vaccine shortage# HTTP://www.telegraph.co.uk/business/2017/08/19/gsk-faces-row-vaccine-shortage/?utm_source=dlvr.it&utm_medium=twitter
philanderer
18/8/2017
14:37
Effectively tracking the index, don't you think?
tradermichael
18/8/2017
14:04
It's down over 1% slightly more than the ftse today.
tim 3
18/8/2017
11:03
GSK holding up decently in the current sell off. Ought to benefit from rotation into safety when profit taking on finance and tech occurs. End of the Trump trade in sight now that he has become a lame duck. No money or support now for financing fantasy infrastrucutre projects and big tax give aways. Debt ceiling row will get sorted in the end, but it was messy enough under Obama, imagine how many months of government shut down it will take with Trump at the helm.
romeike
17/8/2017
19:10
Gary - a well presented post. I entirely agree with your comments about GSK an think Emma is taking a much more structured approach that is well overdue. Also, I must confess I never thought that Hikma would come back so aggressively and to my mind it is buying boots on time!
ianood
17/8/2017
18:29
Trump will hammer pharma's, CEO of Merck started the resignations. Will he seek revenge.
montyhedge
17/8/2017
13:25
Hikma Pharmaceuticals plc’s pain could be GlaxoSmithKline plc’s gain Zach Coffell | Thursday, 17th August, 2017 | More on: GSK HIK Hikma Pharmaceuticals (LSE: HIK) today downgraded its 2017 forecast for the third time this year and now expects revenues of around $2bn, down from previous guidance of $2.1bn-$2.2bn. The announcement of a licensing agreement with Takeda couldn’t prevent the shares from plummeting 9% in early trading, knocking the share price down to nearly half what it was just 12 months ago. The company was hit by the devaluation of the Egyptian pound and an increasingly tough environment in the US where “competition is increasing and pricing pressure is intensifying,” according to CEO Said Darwazah. First-half revenue rose 1%, while operating profit fell 7% after a strong performance in Generics was offset by a weaker showing from Branded Generics. Strong operating cash flow helped the company reduce net debt from $697m to $633m, a perfectly healthy level considering the defensive nature of pharma companies. Investors will surely be disappointed, but some cautiously optimistic comments regarding Hikma’s Advair generic will go some way to soothing long-term fears. Sales of Advair, GlaxoSmithKline̵7;s (LSE: GSK) premier blockbuster drug, have held up better than expected since its patent expired back in 2016, because the Diskus delivery system it employs has been a tough one to crack for both Hikma and rivals Mylan and Novartis alike. Hikma said it has managed to “clarify and resolve” a number of the FDA’s questions regarding the key drug and reiterated there were “no material issues” concerning eventual approval. A more detailed update has been promised, but given the deterioration in the company’s outlook, investors might not relax until more context has been given. These delays are certainly to the benefit of Glaxo. Its massive 5.3% yield is barely covered by cash-flow and the extended no-competition period for Advair grants some much-needed breathing space so it can squeeze more out of its other businesses. Right direction I firmly believe that GSK is moving in the right direction and that a combination of margin expansion and slow-but-steady sales growth will eventually better cover the dividend. If this happens, it would not be surprising to see the shares re-rate to a more normal yield of around 4.5%, indicating a near 20% upside if the market gets comfortable with the payout. The company’s free cash flow jumped from £0.1bn in the first half of this year to £0.4bn, but if it is to achieve its target “to build free cash flow cover of the annual dividend to a target range of 1.25-1.50x,” it must continue its run of form. The rate of inevitable decline in Advair sales will be key for GSK over the next few years, as will performance in its HIV division which has really picked up the slack for the company of late. The firm did warn of “the impact of generic competition to Epzicom/Kivexa,̶1; so investors would do well to keep a close eye of the performance from the HIV treatments in future updates. I find both companies attractive propositions at current prices. Hikma has had a terrible year, but its strong presence in North Africa and the Middle East should continue to drive growth as healthcare spend increases. Similarly, Glaxo might run into some short-term issues covering the dividend, but its pipeline looks bright and I’m cheered by new CEO Emma Wamlsley’s strategic plan, specifically regarding a refocusing of capital allocation in the pharma business.
garycook
17/8/2017
13:17
Gsk did behave like that back in the day, far less so now, FX a major factor. One plus is a significantly weakened Trump cannot touch healthcare now imv.
essentialinvestor
17/8/2017
13:16
Sorry yield now 5.3%!
ny boy
17/8/2017
13:15
Should be a flight to quality here if the general markets pull back, safe haven stock at an attractive entry point in the share chart. I see investors moving in here, the quarterly divi an attraction ..annual yield over 4%
ny boy
17/8/2017
13:09
FX again ATM.
essentialinvestor
17/8/2017
02:57
NYB,Also topped up here and PFC.Now holding 2,450 GSK,and 11,000 PFC.We should see progress in both short term,and long term.
garycook
16/8/2017
20:48
Good find.
dstorey1
16/8/2017
20:34
'GlaxoSmithKline taps Baltimore’s Insilico for AI-based drug discovery' HTTP://www.fiercebiotech.com/medtech/gsk-taps-baltimore-s-insilico-for-ai-based-drug-discovery
philanderer
16/8/2017
12:05
Gary, sorry I hold lots of PFC but nothing more to add there at the moment, I used the pull back to increase my holding. Also I have been busy investing elsewhere. Investors will come back into these, I see them as oversold, not in any rush, as happy raking in the quarterly divi, looking forward to the next pay day in October.
ny boy
16/8/2017
09:03
1725 lol, I would be happy with 1520.
essentialinvestor
16/8/2017
08:50
NY Boy,See you have deserted the PFC thread.Why ?
garycook
16/8/2017
08:38
That would be nice.
warrior boy
16/8/2017
08:14
On the way back to 1725p
ny boy
15/8/2017
20:56
Nicola Sturgeon officially opens GlaxoSmithKline's £44m Montrose facility HTTP://www.insider.co.uk/news/nicola-sturgeon-officially-opens-glaxosmithklines-10992795
philanderer
Chat Pages: 599  598  597  596  595  594  593  592  591  590  589  588  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:40 V: D:20170823 04:06:41